Zobrazeno 1 - 10
of 268
pro vyhledávání: '"Loic Ysebaert"'
Autor:
Sarah Cadot, Chloe Audebert, Charlotte Dion, Soleakhena Ken, Loic Dupré, Laetitia Largeaud, Camille Laurent, Loic Ysebaert, Fabien Crauste, Anne Quillet-Mary
Publikováno v:
PLoS Medicine, Vol 21, Iss 7, p e1004430 (2024)
BackgroundOne of the first clinical observations of ibrutinib activity in the treatment of chronic lymphocytic leukemia (CLL) is a rapid decline in lymph nodes size. This phenomenon is accompanied by an hyperlymphocytosis, either transient or prolong
Externí odkaz:
https://doaj.org/article/f17d8dafc0d34daa9927d03be3be13de
Publikováno v:
Acta Dermato-Venereologica, Vol 104 (2024)
Abstract is missing (Short communication)
Externí odkaz:
https://doaj.org/article/e3b535d67e9e419ea78614314d9c2872
Autor:
Sylvain Carras, Alexia Torroja, Anouk Emadali, Emilie Montaut, Nicolas Daguindau, Adrian Tempescul, Anne Moreau, Emmanuelle Tchernonog, Anna Schmitt, Roch Houot, Caroline Dartigeas, Sarah Barbieux, Selim Corm, Anne Banos, Ludovic Fouillet, Jehan Dupuis, Margaret Macro, Joel Fleury, Fabrice Jardin, Clementine Sarkozy, Ghandi Damaj, Pierre Feugier, Luc Matthieu Fornecker, Cecile Chabrot, Veronique Dorvaux, Krimo Bouabdallah, Sandy Amorim, Reda Garidi, Laurent Voillat, Bertrand Joly, Nadine Morineau, Marie Pierre Moles, Hacene Zerazhi, Jean Fontan, Yazid Arkam, Magda Alexis, Vincent Delwail, Jean Pierre Vilque, Loic Ysebaert, Barbara Burroni, Mary Callanan, Steven Le Gouill, Rémy Gressin
Publikováno v:
Haematologica, Vol 109, Iss 6 (2023)
Between 2011 and 2012, a phase II trial evaluated the use of the RiBVD (rituximab, bendamustine, velcade and dexamethasone) combination as first-line treatment for mantle cell lymphoma (MCL) patients over the age of 65. We have now re-examined the cl
Externí odkaz:
https://doaj.org/article/a4e6dae9b9dd49e895f048451b370929
Autor:
Anne Largeot, Vanessa Klapp, Elodie Viry, Susanne Gonder, Iria Fernandez Botana, Arnaud Blomme, Mohaned Benzarti, Sandrine Pierson, Chloé Duculty, Petra Marttila, Marina Wierz, Ernesto Gargiulo, Giulia Pagano, Ning An, Najla El Hachem, Daniel Perez Hernandez, Supriya Chakraborty, Loic Ysebaert, Jean-Hugues François, Susan Cortez, Guy Berchem, Dimitar G Efremov, Gunnar Dittmar, Martyna Szpakowska, Andy Chevigne, Petr V. Nazarov, Thomas Helleday, Pierre Close, Johannes Meiser, Basile Stamatopoulos, Laurent Désaubry, Jérôme Paggetti, Etienne Moussay
Publikováno v:
HemaSphere, Vol 7, p e52627ab (2023)
Externí odkaz:
https://doaj.org/article/cadb7e0ab439425bb2d02339f658e7b0
Autor:
Pierre Walczak, Sylvain Choquet, Jacques Dantal, David Boutboul, Felipe Suarez, Marine Baron, Veronique Morel, Thomas Cluzeau, Mohamed Touati, Michelle Elias, Emmanuel Bachy, Emmanuelle Nicolas-Virelizier, Roch Houot, Geoffroy Venton, Caroline Jacquet, Marie-Pierre Moles-Moreau, Fabrice Jardin, Eric Durot, Noureddine Balegroune, Laure Ecotiere, Romain Guieze, Nassim Kamar, Loic Ysebaert, Lionel Couzi, Hugo Gonzalez, Louise Roulin, Kevin Ou, Sophie Caillard, Heiner Zimmermann, Ralf Ulrich Trappe, Damien Roos-Weil
Publikováno v:
Haematologica, Vol 108, Iss 10 (2023)
Externí odkaz:
https://doaj.org/article/4fd7c8f1bf3843ebbe6d2663de488a3d
Autor:
Tatiana E. Bialik, Vladimir I. Vorob'ev, Valerii A. Ionin, Loic Ysebaert, Kamil D. Kaplanov, Larisa P. Mendeleeva, Evgenii A. Nikitin, Vadim V. Ptushkin, Olga S. Samoilova, Elena A. Stadnik
Publikováno v:
Современная онкология, Vol 23, Iss 3, Pp 404-406 (2021)
Over the past decades, there has been a significant expansion of the treatment options for patients with chronic lymphocytic leukemia (CLL) due to Brutons tyrosine kinase (BTK) inhibitors, which changed approaches in CLL therapy. Ibrutinib was the fi
Externí odkaz:
https://doaj.org/article/1c92f70a6bda4d418cdf39c54aceadf2
Autor:
Sarah Cadot, Carine Valle, Marie Tosolini, Frederic Pont, Laetitia Largeaud, Camille Laurent, Jean Jacques Fournie, Loic Ysebaert, Anne Quillet-Mary
Publikováno v:
Biomarker Research, Vol 8, Iss 1, Pp 1-13 (2020)
Abstract Background Ibrutinib, an irreversible Bruton Tyrosine Kinase (BTK) inhibitor, has revolutionized Chronic Lymphocytic Leukemia (CLL) treatment, but resistances to ibrutinib have emerged, whether related or not to BTK mutations. Patterns of CL
Externí odkaz:
https://doaj.org/article/e2fc737158c04f7ba4a2fdea4933707f
Autor:
Zara Steinmeyer, Cyrille Delpierre, Gaelle Soriano, Armand Steinmeyer, Loic Ysebaert, Laurent Balardy, Sandrine Sourdet
Publikováno v:
BMC Geriatrics, Vol 20, Iss 1, Pp 1-10 (2020)
Abstract Background Frailty and hemoglobin concentration, above what would be considered clinical anemia, are two common findings in older patients that lead to an increased risk of negative health outcomes. The objective of this study is to evaluate
Externí odkaz:
https://doaj.org/article/4a3169eb5b8e4b5dbfb9df40f6c23f72
Autor:
Martin Gauthier, Françoise Durrieu, Elodie Martin, Michael Peres, François Vergez, Thomas Filleron, Lucie Obéric, Fontanet Bijou, Anne Quillet Mary, Loic Ysebaert
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-11 (2019)
Abstract Background Eradication of minimal residual disease (MRD), at the end of Fludarabine-Cyclophosphamide-Rituximab (FCR) treatment, is a validated surrogate marker for progression-free and overall survival in chronic lymphocytic leukaemia. But s
Externí odkaz:
https://doaj.org/article/ca51332e1168470592babd22abe18c80
Autor:
Loic Ysebaert, Anne Quillet-Mary, Marie Tosolini, Frederic Pont, Camille Laurent, Jean-Jacques Fournié
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
High-definition transcriptomic studies through single-cell RNA sequencing (scRNA-Seq) have revealed the heterogeneity and functionality of the various microenvironments across numerous solid tumors. Those pioneer studies have highlighted different ce
Externí odkaz:
https://doaj.org/article/5381e4055ad240e4af7ab5295a907b0c